For more than 20 years Professor Malyszko has conducted research and clinical work on anaemia and iron metabolism in CKD and renal replacement therapy (RRT). In the early 1990s Professor Malyszko investigated the effect of recombinant human erythropoietin on coagulation, fibrinolysis and inflammation in CKD and RRT.
In the late 1990s, she focused on research into the possible role of hepcidin as an iron gatekeeper in patients with CKD on RRT and patients after heart transplantation with CKD. She conducted studies on the methods of appropriate hepcidin measurement as well as the role of hepcidin in patients with cardiovascular diseases, including heart failure in relation to kidney function.
She then conducted further research in international and national collaborations on other possible markers of iron status in CKD and RRT, including haemojuvelin, GDF15 and sTFR. In addition, she studied the role of non-transferrin bound iron (NTBI) in the CKD/RRT population, the effect of IV iron on NTBI and the problem of absolute and functional iron deficiency in the RRT population.